The group confirmed previous findings showing that SSc typically has an imbalance of T cells and showed that low-dose IL-2 therapy can restore the balance of the Th17 to Treg cell ratio, leading to reduced disease activity in SSc patients [220]. The gene discussed is IL2; the disease is systemic sclerosis.